Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Aug;102(7):535-537.
doi: 10.1111/imcb.12799. Epub 2024 Jun 27.

Striking an alliance between T cells and macrophages for enhanced cancer immunotherapy

Tessa Gargett  1   2   3 , Lisa M Ebert  1   2   3
Affiliations
Comment

Striking an alliance between T cells and macrophages for enhanced cancer immunotherapy

Tessa Gargett et al. Immunol Cell Biol. 2024 Aug.

Abstract

A new study by Yamada-Hunter et al. reveals a novel approach to promote synergy-rather than antagonism-between macrophages and engineered T cells, leading to enhanced antitumor immunity.

Keywords: Antitumor immunity; engineered T cells; macrophages; synergy.

PubMed Disclaimer

Comment on

  • Engineered CD47 protects T cells for enhanced antitumour immunity.
    Yamada-Hunter SA, Theruvath J, McIntosh BJ, Freitas KA, Lin F, Radosevich MT, Leruste A, Dhingra S, Martinez-Velez N, Xu P, Huang J, Delaidelli A, Desai MH, Good Z, Polak R, May A, Labanieh L, Bjelajac J, Murty T, Ehlinger Z, Mount CW, Chen Y, Heitzeneder S, Marjon KD, Banuelos A, Khan O, Wasserman SL, Spiegel JY, Fernandez-Pol S, Kuo CJ, Sorensen PH, Monje M, Majzner RG, Weissman IL, Sahaf B, Sotillo E, Cochran JR, Mackall CL. Yamada-Hunter SA, et al. Nature. 2024 Jun;630(8016):457-465. doi: 10.1038/s41586-024-07443-8. Epub 2024 May 15. Nature. 2024. PMID: 38750365 Free PMC article.

References

REFERENCES

    1. Yamada‐Hunter SA, Theruvath J, McIntosh BJ, et al. Engineered CD47 protects T cells for enhanced antitumour immunity. Nature 2024; 630: 457–465.
    1. Bagley SJ, Binder ZA, Lamrani L, et al. Repeated peripheral infusions of anti‐EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nat Cancer 2024; 5: 517–531.
    1. Choi BD, Gerstner ER, Frigault MJ, et al. Intraventricular CARv3‐TEAM‐E T cells in recurrent glioblastoma. N Engl J Med 2024; 390: 1290–1298.
    1. Mackensen A, Haanen J, Koenecke C, et al. CLDN6‐specific CAR‐T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211‐01 trial. Nat Med 2023; 29: 2844–2853.
    1. Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour‐associated macrophages. Nat Rev Clin Oncol 2022; 19: 402–421.

LinkOut - more resources